Libourne, September 07, 2012:
Ceva Santé Animale launches Cardalis®, a unique tablet combining benazepril and spironolactone, to be prescribed to dogs suffering from heart failure. This latest cardiology innovation provides the powerful combined effect of two active ingredients, in a single easy-to-administer daily tablet for improved compliance.
Dual blockade for a longer life
A combination of an Angiotensin Converting Enzyme inhibitor (ACEi) with an Aldosterone receptor blocker has been proven, in both humans and in dogs, to be better than an ACEi alone to counteract the effects of degenerative heart conditions.
Indeed, dogs suffering from heart failure are 3 times less likely to see their health deteriorate or die due to heart failure (the risk of death alone being 9 times reduced) when spironolactone is combined with benazepril, compared to benazepril alone.
As a result of its high effectiveness, Cardalis® improves the dogs’ quality of life, from the first week of treatment, as assessed by both veterinarians and dog owners.
A single tablet for improved compliance
As heart failure is a chronic condition often requiring polytherapy protocols, owner compliance is a key issue. With only one very small flavoured tablet to give each day, dog owners are overwhelming in favour of Cardalis® compared to 2-tablet treatment regimes.
Consequently, 86.5% of dog owners were compliant with Cardalis® treatments during a 3 month period, whereas in the case of a 2-tablet treatment regime, more than 25% did not comply with treatment just 2 weeks after prescribing. With Cardalis®, it is easier and more cost effective than ever before to treat dogs with heart conditions. Cardalis® will be launched in most European countries this autumn.
As people are living longer, so are their pets. One of Ceva’s key missions is to promote the benefits of the human-animal bond. Our advances in cardiology often mean that the quality of life for both affected dogs and their owners is immeasurably improved.
>> Click on the link below to download the Press Release: